Dossier assessment
Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, 1 to < 3 years) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, 1 to < 3 years) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, 1 to < 3 years) – Benefit assessment according to §35a Social Code Book V
Drug assessment at a glance
-
Drug assessment at a glance
Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, 1 to < 3 years) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Treatment of symptomatic, inoperable plexiform neurofibromas in paediatric patients with neurofibromatosis type 1, aged 1 to < 3 years
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
06-08-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A26-09
- Commission
- Commission awarded on 05.02.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A26-09_en
Connected Projects
-
Addendum
Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, 1 to < 3 years) – Addendum to Project A26-09
Status: Commission completed